Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Long-term Efficacy of Single-agent Vemurafenib for Pleomorphic Xanthoastrocytoma.

Finch EA, Elton SW, Huang BY, Trembath DG, Blatt J.

J Pediatr Hematol Oncol. 2018 Dec 27. doi: 10.1097/MPH.0000000000001395. [Epub ahead of print]

PMID:
30601402
2.

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.

Lukas RV, Merrell RT.

CNS Oncol. 2018 Apr;7(2):CNS10. doi: 10.2217/cns-2017-0032. Epub 2018 Apr 30.

3.

Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I.

Cancer Biol Ther. 2018;19(10):871-874. doi: 10.1080/15384047.2018.1480289. Epub 2018 Jul 23.

PMID:
30036146
4.

Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.

Cicuendez M, Martinez-Saez E, Martinez-Ricarte F, Asanza EC, Sahuquillo J.

J Neurosurg Pediatr. 2016 Jul;18(1):53-7. doi: 10.3171/2016.1.PEDS15558. Epub 2016 Mar 25.

PMID:
27015517
5.

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Thompson EM, Landi D, Ashley D, Keir ST, Bigner D.

J Neurooncol. 2018 Nov;140(2):261-268. doi: 10.1007/s11060-018-2975-5. Epub 2018 Aug 17.

PMID:
30120661
6.

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.

Acta Neuropathol. 2011 Mar;121(3):397-405. doi: 10.1007/s00401-011-0802-6. Epub 2011 Jan 29.

PMID:
21274720
7.

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.

Chamberlain MC.

J Neurooncol. 2013 Sep;114(2):237-40. doi: 10.1007/s11060-013-1176-5. Epub 2013 Jun 12.

PMID:
23756728
8.

Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.

Marton E, Feletti A, Orvieto E, Longatti P.

J Neurol Sci. 2007 Jan 31;252(2):144-53. Epub 2006 Dec 26. Review.

PMID:
17189643
9.

Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma. Case report.

Macaulay RJ, Jay V, Hoffman HJ, Becker LE.

J Neurosurg. 1993 Nov;79(5):761-8.

PMID:
8410257
10.

Complete Remission of an Extracranially Disseminated Anaplastic Pleomorphic Xanthoastrocytoma With Everolimus: A Case Report and Literature Review.

Saraf AJ, Elhawary G, Finlay JL, Scott S, Olshefski R, Halverson M, Boue DR, AbdelBaki MS.

Pediatr Neurol. 2018 Nov;88:65-70. doi: 10.1016/j.pediatrneurol.2018.09.004. Epub 2018 Sep 13. Review.

PMID:
30322731
11.

Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Brown NF, Carter T, Mulholland P.

CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.

12.

BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.

Ma C, Feng R, Chen H, Hameed NUF, Aibaidula A, Song Y, Wu J.

World Neurosurg. 2018 Dec;120:e1225-e1233. doi: 10.1016/j.wneu.2018.09.050. Epub 2018 Sep 18.

PMID:
30240866
13.

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas.

Del Bufalo F, Ceglie G, Cacchione A, Alessi I, Colafati GS, Carai A, Diomedi-Camassei F, De Billy E, Agolini E, Mastronuzzi A, Locatelli F.

Front Oncol. 2018 Nov 14;8:526. doi: 10.3389/fonc.2018.00526. eCollection 2018.

14.

Primary anaplastic pleomorphic xanthoastrocytoma in adults. Case report and review of literature.

Choudry UK, Khan SA, Qureshi A, Bari E.

Int J Surg Case Rep. 2016;27:183-188. doi: 10.1016/j.ijscr.2016.08.022. Epub 2016 Aug 24.

15.

Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.

Amayiri N, Swaidan M, Al-Hussaini M, Halalsheh H, Al-Nassan A, Musharbash A, Tabori U, Hawkins C, Bouffet E.

J Pediatr Hematol Oncol. 2018 Aug;40(6):478-482. doi: 10.1097/MPH.0000000000001032.

PMID:
29200156
16.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
17.

BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK.

Am J Surg Pathol. 2015 Apr;39(4):528-40. doi: 10.1097/PAS.0000000000000363.

18.

Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.

Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV.

Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.

PMID:
30169370
19.

The role of BRAF V600 mutation in melanoma.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N.

J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85.

20.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.

Eur J Cancer. 2015 Jul;51(11):1435-43. doi: 10.1016/j.ejca.2015.04.010. Epub 2015 May 13.

Supplemental Content

Support Center